Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus

Neurogastroenterology and Motility

Volumn 28, Issue 2, 2016, Pages 206-216

  Pini, A ^a   Garella, R ^a   Idrizaj, E ^a   Calosi, L ^a   Baccari, M C ^a   Vannucchi, M G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antineoplastic drug; Gastric epithelium; Myenteric plexus; Nitrergic neurons; Pleiotropic intestinal hormone

Indexed keywords

CISPLATIN; N(G) NITROARGININE; NEURONAL NITRIC OXIDE SYNTHASE; TEDUGLUTIDE; ANTINEOPLASTIC AGENT; GLUCAGON LIKE PEPTIDE 2; PEPTIDE;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MOUSE; MYENTERIC PLEXUS; NEUROPATHY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE CONTRACTION; STOMACH; STOMACH EPITHELIUM; STOMACH FUNDUS; STOMACH MUCOSA INJURY; THICKNESS; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INTESTINE PSEUDOOBSTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CISPLATIN; DISEASE MODELS, ANIMAL; FEMALE; GASTRIC FUNDUS; GLUCAGON-LIKE PEPTIDE 2; IMMUNOHISTOCHEMISTRY; INTESTINAL PSEUDO-OBSTRUCTION; MICE; MICE, INBRED C57BL; MYENTERIC PLEXUS; PEPTIDES;

EID: 84956593963     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12712     Document Type: Article

References (42)

1. Marathe CS, Rayner CK, Jones KL, Horowitz M. Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides 2013; 44: 75-86.
2. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17: 161-71.
3. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93: 7911-6.
4. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol Endocrinol Metab 1997; 273: E77-84.
5. Baldassano S, Amato A, Cappello F, Rappa F, Mulè F. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet. J Endocrinol 2013; 217: 11-20.
6. Hornby PJ, Moore BA. The therapeutic potential of targeting the glucagon- like peptide-2 receptor in gastrointestinal disease. Expert Opin Ther Targets 2011; 15: 637-46.
7. Voss U, Sand E, Hellström PM, Ekblad E. Glucagon-like paptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons. BMC Gastroenterol 2012; 1: 12-30.
8. Rasmussen AR, Viby NE, Hare KJ, Hartmann B, Thim L, Holst JJ, Poulsen SS. The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Dig Dis Sci 2010; 55: 2785-96.
9. Cinci L, Faussone-Pellegrini MS, Rotondo A, Mulè F, Vannucchi MG. GLP-2 receptor expression in excitatory and inhibitory enteric neurons and its role in mouse duodenum contractility. Neurogastroenterol Motil 2011; 23: e383-92.
10. Rowland KJ, Brubaker PL. The "cryptic" mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 2011; 301: G1-8.
11. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999; 96: 1569-73.
12. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005; 124: 105-12.
13. Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin Investig Drugs 2007; 16: 1009-21.
14. Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: mulecular mechanisms of action. Eur J Pharmacol 2014; 740C: 364-78.
15. Khan R, Khan AQ, Qamar W, Lateef A, Ali F, Rehman MU, Tahir M, Sharma S et al. Chrysin abrogates cisplatin-induced oxidative stress, p53 expression, goblet cel disintegration and apoptotic responses in the jejunum of Wistar rats. J Nutr 2012; 108: 1574-85.
16. Di Fiore F, Van Cutsem E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract Res Clin Gastroenterol 2009; 23: 113-24.
17. Cabezos PA, Vera G, Martìn-Fontelles MI, Fernàndez-Puojol R, Abalo R. Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica. Neurogastroenterol Motil 2010; 22: 797-805.
18. Andrews PL, Horn CC. Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 2006; 125: 100-15.
19. Jarve RK, Aggarwal SK. Cisplatin-induced inhibition of the calcium-calmodulin complex, neuronal nitric oxide synthase activation and their role in stomach distension. Cancer Chemother Pharmacol 1997; 39: 341-8.
20. Vera G, Castillo M, Cabezos PA, Chiarlone A, Martin MI, Gori A, Pasquinelli G, Barbara G et al. Enteric neuropathy evoked by repeated cisplatin in the rat. Neurogastroenterol Motil 2011; 23: 370-8.
21. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005; 54: 1224-31.
22. Garella R, Baccari MC. Contribution of endogenous nitrergic and peptidergic influences to the altered neurally-induced gastric contractile responses in strips from dystrophic (mdx) mice. Regul Pept 2010; 160: 57-63.
23. Squecco R, Garella R, Francini F, Baccari MC. Influence of obestatin on the gastric longitudinal smooth muscle from mice: mechanical and electrophysiological studies. Am J Physiol Gastrointest Liver Physiol 2013; 305: G628-37.
24. Vannucchi MG, Garella R, Cipriani G, Baccari MC. Relaxin counteracts the altered gastric motility of dystrophic (mdx) mice: functional and immunohistochemical evidence for the involvement of nitric oxide. Am J Physiol Endocrinol Metab 2011; 300: E380-91.
25. Cabezos PA, Vera G, Castillo M, Fernandez-Pujol R, Martin MI, Abalo R. Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci 2008; 141: 54-65.
26. Takeda N, Hasegawa S, Morita Horii A, Uno A, Yamatodani A, Matsunaga T. Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats. Methods Find Exp Clin Pharmacol 1995; 17: 647-52.
27. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol Endocrinol Metab 1997; 272: E1050-8.
28. Kissow H, Viby NE, Hartmann B, Holst JJ, Timm M, Thim L, Poulsen SS. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemother Pharmacol 2012; 70: 39-48.
29. Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, Mortensen J, Poulsen SS, Quistorff B et al. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009; 2009: 616054.
30. Wafai L, Taher M, Jovanovska V, Bornstein JC, Dass CR, Nurgali K. Effects of oxaliplatin on mouse myenteric neurons and colonic motility. Front Neurosci 2013; 7: 1-7.
31. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003; 182: 12-20.
32. Stojanovska V, Sakkal S, Nurgali K. Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am J Physiol Gastrointest Liver Physiol 2015; 308: G223-32.
33. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012; 14 (Suppl. 4): iv45-54.
34. Lefebvre RA, De Vriese A, Smits GJ. Influence of vasoactive intestinal polypeptide and NG-nitro-L-arginine methyl ester on cholinergic neurotransmission in the rat gastric fundus. Eur J Pharmacol 1992; 221: 235-42.
35. Schmidt Y, Unger JW, Bartke I, Reiter R. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol 1995; 132: 16-23.
36. Leung EL, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Br J Cancer 2008; 98: 1803-9.
37. Giaroni C, Marchet S, Carpanese E, Prandoni V, Oldrini R, Bartolini B, Moro E, Vigetti D et al. Role of neuronal and inducible nitric oxide synthases in the guinea pig ileum myenteric plexus during in vitro ischemia and reperfusion. Neurogastroenterol Motil 2013; 25: e114-26.
38. Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 2005; 128: 1340-53.
39. Jeppesen PB. New approaches to the treatments of short bowel syndrome-associated intestinal failure. Curr Opin Gastroenterol 2014; 30: 182-8.
40. Jeppesen PB. Gut hormones in the treatment of short-bowel syndrome and intestinal failure. Curr Opin Endocrinol Diabetes Obes 2015; 22: 14-20.
41. Thulesen J, Hartmann B, Hare KJ, Kissow H, Ørskov C, Holst JJ, Poulsen SS. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasm in mice. Gut 2004; 53: 1145-50.
42. Trivedi S, Wiber SC, El-Zimaity HM, Brubaker PL. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol 2012; 302: G840-9.